McAbs are ideal tools for analysing complex mixtures of cells and cell lineages. Embryonal carcinoma cells (ECC) are the pluri-potent stem cells of mouse teratocarcinomas. As well as in vivo differentiation these cells can also be induced to differentiate in vitro. This differentiation has been studied by McAbs which are specific either for the stem cell population or the differentiated derivatives. In comparison with the mouse system little is known about the biology of human teratocarcinomas. We have isolated human ECC from testicular teratocarcinomas by passage through nude mice. The stem cells have been defined by the ability to differentiate in vitro and in vivo and reactivity with several different McAbs. Using these reagents we have defined conditions which result in the production of neurons in culture. We re-examined, using monoclonal anti A and anti B reagents, the ABO status of several kinds of tumours:
ANTIGEN-ANTIBODY INTERACTIONS
1. Transitional epithelial cell carcinomas of the bladder -8/39 of these lacked expected blood group isoantigen and this loss correlated with incidence of invasive recurrence (Finan et al. (1982) , Br. J. Urol. 54, 720). 2. Gastric carcinoma -complete loss of isoantigen expression in 6/17 cases (Finan et al. (1983) , J. Natl Cancer Inst. 80, 679 Using a paired antibody technique (including specific and non-specific radio-iodinated antibodies) we showed that although good tumour to nontumour (T:NT) ratios could be obtained in patients with various epithelial neoplasms, the absolute amount of specific radiolabelled antibody targeted to tumours was small (-0.01% of injected amount g 1 tumour 1 day post-administration).
Thus, we investigated other routes of antibody administration. We found improved T:NT and significantly higher absolute antibody uptake when radiolabelled antibodies were given i.p. to patients with ovarian cancer, intralymphatically to patients with lymph node metastases secondary to cervical cancer, intrapleurally to patients with intractable pleural effusion, intrapericardially to patients with pericardial effusion and impending cardiac tamponade, and as an intra-arterial infusion in patients with gliomas. Forty-six patients were examined on a 0.15 Tesla superconducting imaging system before and after intravenous administration of Gd-DTPA (Schering) in a dose of 0.1mmolkg-. The 46 patients included 20 with malignant cerebral tumours, 5 with non-malignant disease of the brain, 12 with tumours of the liver (benign and malignant), 5 with renal tumours, as well as patients with tumours in the bladder, pancreas, femur and mediastinum. All 20 patients with cerebral tumours showed enhancement. In 14/20 cases, contrast enhancement allowed the differentiation between tumoral and peritumoral oedema to be made. Enhancement was noted in all the other patients with the effects being most marked on inversion recovery scans. No significant abnormality was noted in any haematological or biochemical parameter after Gd-DPTA administration. Intravenous Gadolinium-DPTA promises to be a useful adjunct in magnetic resonance imaging. With the advent of positron emission tomography it has become possible to measure the regional tissue concentration of a positron emitting radionuclide in absolute units (Bq ml-'). Using the sequentially inhaled tracers C'502 and "CO it is possible to measure regional blood flow and blood volume in man non-invasively. The uptake of any blood-borne tracer is governed not only by regional tissue perfusion (supply), but also by the regional extraction by the tissue. Consequently by measuring both the regional tissue uptake of a tracer and regional blood flow one can derive the regional extraction of the tracer by means of positron emission tomography. It is relatively easy to correct for the blood pool by using the regional blood volume data obtained after the inhalation of "CO. In some of the examinations we have used SPECT with a rotating gamma camera in combination with conventional gamma camera scintigraphy.
In an attempt to improve the results we have used, in the last year, monkey anti-CEA and monoclonal mouse anti-CEA (McAb 38S1 The aim of this study was to examine the clinical value of radioimmuno-localisation in patients with carcinoma of the ovary, cervix uteri and breast using the tumour-associated McAb HMFG2.
Fifteen patients were studied and the results from antibody scans were compared to surgical findings. 123I labelled antibody was given to patients either i.v. or s.c. Both routes of administration were found to be of clinical value. The i.v. route was useful in establishing the diagnosis and in the follow-up of patients, whilst the s.c. route was useful in the preoperative assessment of lymph node status. The number of patients studied so far is small but the accuracy of this test appears to be high.
In 1969 Gitsch and co-workers introduced intraoperative lymphoscintigraphy in an attempt to improve the accuracy of lymph node dissection in patients with cervical cancer. It is possible that the accuracy of lymphoscintigraphy could be improved by using radiolabelled McAbs Under defined conditions, T101-A-IT allowed: (1) a reduction of the PHA, con A and mixed lymphocyte culture to levels below background; (2) a cyto-reduction of more than 2 logs of the mature T lymphocytes evaluated in a clonogenic assay.
With regard to tolerance, no toxicity of stem cells could be found using CFU-GM, BFU-E and CFU-GEMM assays up to the concentration of 10-8M. These results show that the use of T101-A-IT is a simple, reliable, highly efficient and safe approach to the in vitro treatment of bone marrow in allogeneic transplantation. al., 1983, Blood, 62, 873) , with specificity for human lymphocytes is presently being tested clinically for its ability to prevent GvHD in bone marrow transplantation. Complement mediated lysis with IgG antibodies of less potency can be improved by preparing the monovalent antibody (Cobbold & Waldmann, 1984, Nature, in press ).
In tests of antibody dependent cell-mediated cytotoxicity using human lymphocytes as effectors no killing was observed with 18 IgM, 23 IgG2a or 4 IgG2c antibodies but all 21 IgG2b antibodies tested gave killing even at high dilution (Hale et al., 1984, Biochem. Soc. Trans., in press ).
Various isotypes of rat antibodies against mouse lymphocyte subpopulations were tested for their ability to suppress in vivo immune responses and graft rejection. Only antibodies of the IgG2b isotype were found to work (Cobbold et al., 1983, Mol. Biol. Med., 1, 285 From the results it is self-evident that a high tumour uptake contributes to increased tumour dose. Less obvious is the dosimetric consequences of the interplay between isotope half-life, antibody uptake and subsequent loss from the tumour. A long-lived isotope gives a low body dose when en route to the target and allows more time for clearance from normal tissues while tumour irradiation is proceeding. Both these effects act to increase tumour specificity and depend upon a prolonged tumour residence time for the isotope. Currently the isotope which appears most suitable as a toxic radiolabel is the 64 h half-life beta emitter, 90-Yttrium, incorporated in a chelate link (as with 111-Indium) onto the antibody. F(ab')2 fragments of two McAbs H 1 7E2 and AUA-1 were prepared by pepsin digestion of the Ig and purified by affinity and size exclusion chromatography. Direct binding radioassays were performed on purified antigen preparations or relevant tumour cell lines either in solid phase or as live cell suspensions. Biodistribution experiments were performed in nude mice bearing colorectal tumour xenografts using radiolabelled Ig and F(ab')2 preparations. Clearance rates, tumour uptake and tumour (T) to blood (B) and tumour to organ (0) ratios for the two antibody species were calcujated. In general T:B and T:O ratios for F(ab')2 were significantly higher than for intact antibody. F(ab')2 clearance rates were faster while absolute tumour uptakes were similar.
These results suggest that, for diagnostic immunoscintigraphy, radiolabelled F(ab')2 preparations are likely to be preferable to intact Igs. In this study McAb 96.5, specific for melanoma antigen p97, was labelled with 1251 by three different techniques: Lactoperoxidase (LPO), Cloramine-T (CLT) and Bolton-Hunter (BH). As a control the antibody 1.4 (labelled with 13l1) or human serum albumin was used for evaluation of non-specific uptake. The blood pool was evaluated in the tumour with in vivo 9QTcm-labelled red blood cells.
Blood flow measurements were performed with a microspheres technique.
Nude athymic rats, weighing 150-300 g (n = 70), transplanted with human melanoma were used as animal model. Scintillation camera measurements and blood samples were taken during 1 to 5 days. The rats were then sacrificed and tissue samples were measured for radioactivity. The specific activity uptake in the tumour for the McAb 96.5 was dependent on tumour wt. For tumours weighing <0.3g the specific uptake was 2-3 times higher than for larger tumours. The biological halflife in the whole body was -80-125h for antibody 96.5 and 30-50 h for control antibody 1.4. Tumour/organ ratios were calculated and in the order of 0.3-0.6 for T/blood, 1.9-2.0 for T/liver and 3.3-4.6 for T/muscle.
This In the investigation presented here, we examined the cell surface changes, the membrane traffic of 75-Se-methionine and growth delay of cultured rat glioma cells in the presence of the McAb 14AC1. The production and characterization of the antibody used was described recently (Stavrou et al. (1983 Eur. J. Cancer Clin. Oncol., 19, 1439 Preliminary studies using the immunoperoxidase technique indicated that CAM5.2 positively stained the endocervical glands of the normal cervix, as opposed to the ectocervix, which was negative: all invasive carcinomas of the cervix stained positively.
The change in expression of cytokeratin polypeptides with the development of malignancy in the cervix has been assessed in varying degrees of intraepithelial neoplasia and invasive carcinoma. Uniformly positive staining was noted in all invasive carcinomas, whereas the 10 cases of intraepithelial neoplasia studied were generally negative with some areas of equivocal staining. Our results suggest that as the extocervic becomes more dysplastic the cells start to manufacture the lower mol. wt., more embryonic forms of cytokeratin polypeptides. Placental-type alkaline phosphatases comprise a polymorphic group of enzymes in which two major forms can be distinguished: the "placental" and "placental-like" alkaline phosphatases (PLAP and placental-like AP, respectively). Both forms of the enzyme have been described as tumour products, and these correspond to the so-called Regan (PLAP) and Nagao (placental-like AP) enzymes. We have studied in depth a McAb H317 reactive with PLAP but not with placental-like AP or any non-placental tissue alkaline phosphatase isoenzymes. This McAb has formed the basis of a solid-phase enzyme immunoassay detecting >0.1 U I1 PLAP (McLaughlin (1983) et al., Clin Chim. Acta, 130, 199) . In this assay 26/65 (40%) of ovarian cancer sera had detectable PLAP whereas PLAP was not found in any control sera. It appears that the circulating form of enzyme in healthy individuals is the placental-like AP and is thus unreactive with H3 17 (McLaughlin et al. (1984) J. Clin. Pathol., in press). Thus, H317 may detect a more specific tumour marker within this enzyme group. The H317 McAb is also being used in in vivo antibody-guided radioimaging of ovarian cancer patients. The aim of this study is to evaluate 123I-labelled H317 McAb as a radioimaging agent for epithelial ovarian tumours 1-4 years after removal of the primary. The patient is injected i.v. with 74 MBq (2mCi) 123I-H317 (2mg mouse IgG). Using a large field of view gamma camera, anterior and posterior images are made at 10min, 4h and 24 h. In a preliminary study on 9 patients, three patterns of distribution were seen, viz. (i) focal accumulation of the 123I-H317 in areas of secondary involvement, (ii) diffuse uptake in abdomen and pelvis, and (iii) "cold" areas. 
